CSPAN2 Key Capitol Hill Hearings September 23, 2014
We also need a robust pipeline of discovery thatll lead to new drug candidates for all different kinds of infections. So the limited population idea and the streamlining of Clinical Trials which wouldnt just decrease the time frame, it also decreases the cost and the, you know, the number of people needed, so it would do a number of things, that is one thing that we can do at fda that we think would be beneficial and would be beneficial for patients, but its not going to fix this problem we have of investment. Thank you, mr. Chairman. I yield back. I think that concludes this round of question...
Source: archive.org
